ALNY - Alnylam outlines 2022 product and pipeline goals as part of R&D day

Alnylam Pharmaceuticals (NASDAQ:ALNY) says it plans to launch vutrisiran for hATTR amyloidosis in the U.S. early next year following anticipated FDA approval. The biotech anticipates approval of the drug in Europe in mid-2022. Alnylam will begin a phase 3 study of the drug in Stargardt Disease study in late 2022. The biotech anticipates both submitting an IND and starting a phase 1 study in late 2022 for ALN-TTRsc04 for ATTR amyloidosis. Alnylam plans to complete enrollment in a phase 2 study of lumasiran for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in late 2022. A phase 2 trial of zilebesiran for hypertension is expected to complete enrollment in mid-2022 with top-line results anticipated in late 2022. Alnylam also plans to initiate a phase 1 study of ALN-APP in early-onset Alzheimer's early next year with top-line results in late 2022. A news report his week said that

For further details see:

Alnylam outlines 2022 product and pipeline goals as part of R&D day